Rocuronium Bromide Injection

Rocuronium bromide is an adjuvant drug for general anesthesia, used for endotracheal intubation during routine induction of anesthesia and maintenance of intraoperative muscle relaxation.

This product is administered intravenously, and the starting dose for endotracheal intubation is 0.6 mg/kg. The neuromuscular blockade time for intubation is 0.4 to 6 minutes, with an average of 1 minute. At a dose of 0.6 to 1.2 mg/kg, excellent or good conditions for intubation will be provided within 2 minutes. The clinical maintenance dose of this product is 0.1 mg/kg, 0.15 mg/kg and 0.2 mg/kg. From the intubation dose, the patient can start to use a drip dose of 0.01 to 0.012 mg/(kg.min) after spontaneous breathing is restored. The administration of this product should be individualized. In clinical trials, the drip rate range is 0.004 to 0.016 mg/(kg.min). The dosage for each patient should take into account the duration of the operation, the interaction with other drugs, and the patient's condition, and appropriate neuromuscular monitoring should be performed. Adults can use a dose of 0.6 mg/kg regardless of the length of the operation. If it is a continuous infusion, first give 0.6 mg/kg, then give at a rate of 0.3-0.6 mg (kg.h) to maintain neuromuscular blocking effect, but the blockade must be monitored. Children are as sensitive as adults under halothane anesthesia, but the onset of action is faster. The sensitivity of the elderly to this product is similar to that of adults, but the duration of action is longer.

This product has no significant effect on the cardiovascular system, nor does it release histamine in the body. No obvious accumulation effect has been observed after repeated administration. Therefore, this product is a safe, effective, and fast-acting neuromuscular blocking drug. Since this product has no reported effects on fertility, pregnant women cannot use it for the time being.

1. Those who have had allergic reactions to rocuronium or bromide ions or any ingredients in this product in the past; 2. There is not enough data to evaluate the potential harm of rocuronium to the fetus during human pregnancy, and there is no animal research data to indicate such side effects. For pregnant women, the use of rocuronium should be decided by the attending physician after weighing the pros and cons. Since magnesium salts can enhance neuromuscular blockade, the antagonism of residual muscle relaxation in parturients receiving magnesium salts for the treatment of preeclampsia may be unsatisfactory or inhibited. Therefore, the dosage of rocuronium in these patients should be reduced, and the dose should be titrated according to the twitch reaction. The concentration of rocuronium was not significant in the milk of lactating rats, and there is no data on the use of rocuronium during human lactation. Therefore, rocuronium can only be used in lactating women when the attending physician believes that the benefits outweigh the risks.

Precautions during pregnancy and lactation: Use with caution in pregnant and lactating women.

Chlorpromazine, morphine, thiopental sodium, ketamine, etc. can enhance the effect of this product. When used together, close observation and timely adjustment of dosage are required.

The shelf life is 3 years under specified conditions. This product does not contain preservatives. Use it immediately after opening the ampoule. Store at 2-8℃ away from light. It can be stored at 8-30℃ for 12 weeks.

5ml:50mg

Guangdong Sunho Pharmaceutical Co., Ltd.

• Founded in:

  2005-06-13

• Address:

  No. 17, Jiankang Road, National Health Base, Zhongshan Torch Development Zone

• Tax NO.:

  914420007762231990

• Registered Funds:

  253.47694 million yuan

• Website:

  Log in to view

• Email:

  Log in to view